Figure 3
From: Anti-inflammation-based treatment of atherosclerosis using Gliclazide-loaded biomimetic nanoghosts
(A) Gliclazide release profile from nanoghosts (NG); (B) Hemolytic activity of drug loaded monocytes-based nanoghosts. Error bars show the standard deviation of triplicate measurements, and (C) demonstrates the hemolytic percentages of RBC exposed to different concentrations of NG compared to positive and negative controls.
